ECMO 기기 시장 예측(-2030년) : 제품 유형별, 모달리티별, 환자 유형별, 용도별, 최종사용자별

The ECMO machines market is projected to reach USD 0.86 billion by 2030 from USD 0.65 billion in 2025, at a CAGR of 5.8% during the forecast period.

In recent years, ECMO machines have evolved from bulky, manual-intensive systems to compact, automated, and highly efficient platforms. Next-generation ECMO integrates real-time monitoring, automated flow adjustments, and artificial intelligence (AI)-driven oxygenation control to reduce the need for constant manual intervention. Companies such as Getinge AB and Medtronic are leading in portable ECMO innovations, enabling smoother inter-hospital and intra-hospital patient transfers. Some systems now feature wireless connectivity and cloud-based monitoring, allowing specialists to track remote patient data. Improved centrifugal pumps and polymethyl pentene (PMP) oxygenators enhance durability and reduce complications such as hemolysis or clot formation.

Moreover, innovations in anticoagulation management reduce the risks of bleeding, a historical challenge for ECMO patients. These technological leaps improve patient survival and make ECMO more user-friendly for hospitals with limited staff, driving wider adoption across developed and emerging healthcare markets.

Based on product, the market of ECMO machines is divided into components and ECMO machines. In 2024, the components segment held the largest share of the global ECMO machines market. With the rising incidence of acute respiratory distress syndrome (ARDS), cardiac arrest, and multi-organ failure, ECMO usage has expanded globally across tertiary hospitals. Each ECMO procedure consumes oxygenators, pumps, tubing sets, controllers, and cannulas. Even in short-term ECMO, components like oxygenators and cannulas are single-use, while pumps require precise compatibility and often get upgraded with each procedure. Post-pandemic preparedness further contributes to higher ECMO use, ensuring steady turnover of components. Unlike the machine itself, which remains constant, the increasing number of procedures fuels exponential growth in the component segment.

Based on patient type, the ECMO market has been categorized into adults, pediatrics and neonates. In 2024, adults held the largest market share in the ECMO machines market. The COVID-19 pandemic highlighted ECMO's role in treating severe respiratory failure in adults. During the peak, most ECMO-supported cases were adults with severe ARDS. Even after the acute pandemic phase, many survivors experienced long-term pulmonary damage, fibrosis, and other respiratory complications that increased ECMO utilization in critical cases. Post-COVID-19 complications like myocarditis and post-viral pneumonia also primarily affect adults, contributing to higher demand for ECMO in this age group. Hospitals worldwide expanded ECMO infrastructure during the pandemic, with a focus on adult ICUs, leaving a long-term impact on equipment adoption. This legacy effect ensured that adults continued to account for the largest ECMO market share in 2024.

North America is expected to account for the largest share of the ECMO machines market during the forecast period. North America, particularly the US and Canada, benefits from a highly advanced healthcare ecosystem equipped with top-tier hospitals, critical care units, and specialized medical centers. These facilities can support sophisticated and resource-intensive technologies such as ECMO. Large tertiary hospitals and academic medical centers often serve as hubs for ECMO procedures, offering advanced ICUs and trained multidisciplinary teams that ensure effective patient management. In contrast to emerging regions, North American hospitals possess the financial and infrastructural capacity to invest in expensive ECMO equipment and maintain it efficiently. Furthermore, strong integration of digital health systems, including advanced monitoring tools, ensures safe ECMO management. This infrastructure readiness makes it feasible for ECMO adoption at scale, enhancing accessibility and increasing survival outcomes. As a result, the well-developed healthcare network plays a central role in reinforcing North America's leadership in the ECMO machines market.

A breakdown of the primary participants (supply-side) for the ECMO machines market referred to in this report is provided below:

• By Company Type: Tier 1: 34%, Tier 2: 38%, and Tier 3: 28%
• By Designation: C Level: 26%, Director Level: 35%, and Others: 39%
• By Region: North America: 17%, Europe: 39%, Asia Pacific: 28%, Latin America: 8%, Middle East & Africa: 3%, GCC Countries: 5%

Prominent players in the ECMO machines market are Fresenius Medical Care AG & Co. KGaA (Germany), Getinge AB (Sweden), Medtronic (Ireland), Terumo Corporation (Japan), and LivaNova PLC (UK).

Research Coverage

The report evaluates the ECMO machines market and estimates the market size and future growth potential based on various segments, including product, modality, patient type, application, end user, and region. The report also includes a competitive analysis of the major players in this market, along with company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report

The report will assist the market leader/new entrants with data on the nearest approximations of the revenue numbers for the overall ECMO machines market and the subsegments. The report will assist stakeholders in understanding the competitive landscape and gain further insights into better positioning their businesses and making appropriate go-to-market strategies. The report assists the stakeholders in understanding the market pulse and gives them data on influential drivers, hindrances, obstacles, and opportunities in the market.

This report provides insights into the following points:

• Analysis of key drivers (Increasing prevalence of cardiovascular and respiratory diseases, Growing adoption of ECMO in lung transplantation procedures), restraints (Complications associated with ECMO, High cost of ECMO procedures), opportunities (Increasing survival rates with ECMO), and challenges (Shortage of skilled professionals, Eligibility issues for ECMO)
• Product Launches/Innovations: Comprehensive details about product launches and anticipated trends in the global ECMO machines market
• Market Development: Thorough knowledge and analysis of the profitable rising markets by product, modality, patient type, application, end user, and region
• Market Diversification: Comprehensive information about newly launched products and services, expanding markets, current advancements, and investments in the global ECMO machines market
• Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings, and capacities of the major competitors in the global ECMO machines market

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key data from primary sources
    • 2.1.2.2 Key industry insights
• 2.2 MARKET SIZE ESTIMATION
• 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.4 MARKET SHARE ESTIMATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 ECMO MACHINES MARKET OVERVIEW
• 4.2 ASIA PACIFIC: ECMO MACHINES MARKET, BY PRODUCT AND COUNTRY (2024)
• 4.3 ECMO MACHINES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 4.4 ECMO MACHINES MARKET, REGIONAL MIX, 2023-2030
• 4.5 ECMO MACHINES MARKET: EMERGING VS. DEVELOPED ECONOMIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing prevalence of cardiovascular and respiratory diseases
    • 5.2.1.2 Growing adoption of ECMO in lung transplantation procedures
    • 5.2.1.3 Rise in ECMO centers worldwide
    • 5.2.1.4 Technological advancements in ECMO machines
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Complications associated with ECMO
    • 5.2.2.2 High cost of ECMO procedures
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Increasing survival rates with ECMO
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Shortage of skilled professionals
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.4 PRICING ANALYSIS
  • 5.4.1 AVERAGE SELLING PRICE OF KEY PLAYERS, BY TYPE
  • 5.4.2 AVERAGE SELLING PRICE TREND, BY REGION
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 SUPPLY CHAIN ANALYSIS
• 5.7 ECOSYSTEM ANALYSIS
• 5.8 INVESTMENT AND FUNDING SCENARIO
• 5.9 TECHNOLOGY ANALYSIS
  • 5.9.1 KEY TECHNOLOGIES
    • 5.9.1.1 Advanced oxygenator design
    • 5.9.1.2 High-efficiency blood pumps
  • 5.9.2 COMPLEMENTARY TECHNOLOGIES
    • 5.9.2.1 Advanced hemodynamic monitoring systems
    • 5.9.2.2 Ventilators
  • 5.9.3 ADJACENT TECHNOLOGIES
    • 5.9.3.1 Wearable Artificial Lungs (WALs)
    • 5.9.3.2 Perfusion systems
• 5.10 INDUSTRY TRENDS
  • 5.10.1 GROWING ADOPTION OF ECMO IN NON-TRADITIONAL CARE SETTINGS
  • 5.10.2 INCREASING USE OF ECMO IN PEDIATRIC AND NEONATAL CARE
  • 5.10.3 SHIFT TOWARD ECMO CENTERS OF EXCELLENCE AND REGIONALIZATION
  • 5.10.4 GROWTH OF ECMO SIMULATION TRAINING AND TELE-ECMO PROGRAMS
• 5.11 PATENT ANALYSIS
• 5.12 TRADE ANALYSIS
  • 5.12.1 IMPORT DATA FOR HS CODE 901890
  • 5.12.2 EXPORT DATA FOR HS CODE 901890
• 5.13 KEY CONFERENCES AND EVENTS, 2025-2026
• 5.14 CASE STUDY ANALYSIS
  • 5.14.1 CASE STUDY 1: IMPROVED SURVIVAL RATES IN US USING ECMO
  • 5.14.2 CASE STUDY 2: NEONATAL ECMO PROGRAM IN UK
  • 5.14.3 CASE STUDY 3: MOBILE ECMO TRANSPORT SERVICE IN GERMANY
• 5.15 REGULATORY LANDSCAPE
  • 5.15.1 REGULATORY ANALYSIS
    • 5.15.1.1 North America
      • 5.15.1.1.1 US
      • 5.15.1.1.2 Canada
    • 5.15.1.2 Europe
      • 5.15.1.2.1 Germany
      • 5.15.1.2.2 France
      • 5.15.1.2.3 UK
    • 5.15.1.3 Asia Pacific
      • 5.15.1.3.1 China
      • 5.15.1.3.2 Japan
      • 5.15.1.3.3 India
    • 5.15.1.4 Latin America
      • 5.15.1.4.1 Brazil
      • 5.15.1.4.2 Mexico
    • 5.15.1.5 Middle East & Africa
      • 5.15.1.5.1 South Africa
      • 5.15.1.5.2 GCC Countries
  • 5.15.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.16 PORTER'S FIVE FORCES ANALYSIS
  • 5.16.1 BARGAINING POWER OF SUPPLIERS
  • 5.16.2 BARGAINING POWER OF BUYERS
  • 5.16.3 THREAT OF NEW ENTRANTS
  • 5.16.4 THREAT OF SUBSTITUTES
  • 5.16.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.17 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.17.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.17.2 BUYING CRITERIA
• 5.18 UNMET NEEDS/END-USER EXPECTATIONS
• 5.19 ADJACENT MARKET ANALYSIS
• 5.20 IMPACT OF AI/GEN AI ON ECMO MACHINES MARKET
  • 5.20.1 INTRODUCTION
  • 5.20.2 MARKET POTENTIAL OF GEN AI ON ECMO MACHINES MARKET
  • 5.20.3 AI USE CASES
  • 5.20.4 KEY COMPANIES IMPLEMENTING AI
  • 5.20.5 FUTURE OF GEN AI IN ECMO MACHINES MARKET
• 5.21 IMPACT OF 2025 US TARIFF ON ECMO MACHINES MARKET
  • 5.21.1 KEY TARIFF RATES
  • 5.21.2 PRICE IMPACT ANALYSIS
  • 5.21.3 KEY IMPACT ON COUNTRY/REGION
    • 5.21.3.1 US
    • 5.21.3.2 Europe
    • 5.21.3.3 Asia Pacific
  • 5.21.4 IMPACT ON END-USE INDUSTRIES

6 ECMO MACHINES MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 COMPONENTS
  • 6.2.1 OXYGENATORS
    • 6.2.1.1 Significantly less priming volume associated with PMP oxygenators to boost demand
  • 6.2.2 PUMPS
    • 6.2.2.1 Pivotal role played by centrifugal blood pumps in adult extracorporeal life support to support market growth
  • 6.2.3 CONTROLLERS
    • 6.2.3.1 Ability of controllers to allow operators of ECMO circuits to adjust settings as needed to drive demand
  • 6.2.4 CANNULAS
    • 6.2.4.1 Importance of cannulas in optimizing ECMO flows to boost market
  • 6.2.5 ACCESSORIES
• 6.3 MACHINES
  • 6.3.1 ADVANTAGES SUCH AS TIMELY INTERVENTION IN CASES OF RESPIRATORY AND CARDIAC EMERGENCIES TO FUEL GROWTH

7 ECMO MACHINES MARKET, BY MODALITY

• 7.1 INTRODUCTION
• 7.2 VENOVENOUS ECMO
  • 7.2.1 LOWER INCIDENCE OF NEUROLOGIC COMPLICATIONS AND LACK OF ARTERIAL COMPROMISE TO BOOST GROWTH
• 7.3 VENOARTERIAL ECMO
  • 7.3.1 INCREASING INCIDENCE OF HEART-LUNG FAILURE TO DRIVE GROWTH
• 7.4 ARTERIOVENOUS ECMO
  • 7.4.1 PORTABILITY OF ARTERIOVENOUS ECMO MACHINES TO DRIVE DEMAND

8 ECMO MACHINES MARKET, BY PATIENT TYPE

• 8.1 INTRODUCTION
• 8.2 ADULT PATIENTS
  • 8.2.1 TECHNOLOGICAL ADVANCEMENTS TO DRIVE USE OF ECMO IN ADULT PATIENTS
• 8.3 PEDIATRIC PATIENTS
  • 8.3.1 RECENT ADVANCES IN ECMO TO BOOST MARKET GROWTH
• 8.4 NEONATES
  • 8.4.1 INCREASING UTILIZATION OF ECMO TO MANAGE NEONATES WITH CARDIAC AND RESPIRATORY FAILURE TO SUPPORT GROWTH

9 ECMO MACHINES MARKET, BY APPLICATION

• 9.1 INTRODUCTION
• 9.2 RESPIRATORY APPLICATIONS
  • 9.2.1 INCREASING CASES OF ACUTE RESPIRATORY DISTRESS SYNDROME, PNEUMONIA, AND INFLUENZA TO SPUR GROWTH
• 9.3 CARDIAC APPLICATIONS
  • 9.3.1 RISING PREVALENCE OF CARDIOVASCULAR DISEASES WORLDWIDE TO SUPPORT GROWTH
• 9.4 EXTRACORPOREAL CARDIOPULMONARY RESUSCITATION
  • 9.4.1 GROWING CLINICAL EVIDENCE SUGGESTING IMPROVED SURVIVAL RATES AND NEUROLOGICAL OUTCOMES TO FUEL MARKET

10 ECMO MACHINES MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 HOSPITALS
  • 10.2.1 GROWING USE OF ECMO FOR MANAGING CRITICAL CONDITIONS TO DRIVE MARKET
• 10.3 ACADEMIC & RESEARCH INSTITUTIONS
  • 10.3.1 INCREASING MEDICAL COLLEGES AND RESEARCH FACILITIES INVESTING IN ECMO SYSTEMS TO FOSTER GROWTH
• 10.4 SPECIALTY CLINICS
  • 10.4.1 RISING NEED FOR ADVANCED, LIFE-SAVING INTERVENTIONS TO AID GROWTH

11 ECMO MACHINES MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 11.2.2 US
    • 11.2.2.1 US to account for largest share of North American market
  • 11.2.3 CANADA
    • 11.2.3.1 Implementation of ABF model in Canadian hospitals to drive market growth
• 11.3 EUROPE
  • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 11.3.2 GERMANY
    • 11.3.2.1 Increasing volume of ECMO procedures to drive market growth in Germany
  • 11.3.3 FRANCE
    • 11.3.3.1 Rising healthcare spending to drive market growth in France
  • 11.3.4 UK
    • 11.3.4.1 Significant investment in healthcare to support adoption of advanced medical technologies like ECMO
  • 11.3.5 ITALY
    • 11.3.5.1 High burden of CVDs to contribute to growth of ECMO machines market in Italy
  • 11.3.6 SPAIN
    • 11.3.6.1 High adoption of advanced technologies to drive market growth in Spain
  • 11.3.7 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 11.4.2 JAPAN
    • 11.4.2.1 Favorable healthcare infrastructure in Japan to drive market growth
  • 11.4.3 CHINA
    • 11.4.3.1 Large patient population and government-backed critical care infrastructure expansion to fuel growth
  • 11.4.4 INDIA
    • 11.4.4.1 Growing applications and rising adoption of ECMO to drive market growth in India
  • 11.4.5 SOUTH KOREA
    • 11.4.5.1 Advanced healthcare infrastructure and early ECMO adoption to position South Korea as leading regional market
  • 11.4.6 AUSTRALIA
    • 11.4.6.1 Rising respiratory and cardiac complications, coupled with aging population, to fuel ECMO adoption
  • 11.4.7 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 11.5.2 BRAZIL
    • 11.5.2.1 Rising adoption of ECMO as bridge to heart and lung transplantation to drive market growth in Brazil
  • 11.5.3 MEXICO
    • 11.5.3.1 High burden of CVDs in country to drive market growth in Mexico
  • 11.5.4 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST & AFRICA
  • 11.6.1 INCREASING PREVALENCE OF TARGET DISEASES TO DRIVE MARKET GROWTH IN MIDDLE EAST & AFRICA
  • 11.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
• 11.7 GCC COUNTRIES
  • 11.7.1 RISING INVESTMENTS IN ADVANCED HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
  • 11.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES

12 COMPETITIVE LANDSCAPE

• 12.1 OVERVIEW
• 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
• 12.3 REVENUE ANALYSIS, 2020-2024
• 12.4 MARKET SHARE ANALYSIS, 2024
• 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 12.5.1 STARS
  • 12.5.2 EMERGING LEADERS
  • 12.5.3 PERVASIVE PLAYERS
  • 12.5.4 PARTICIPANTS
  • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 12.5.5.1 Company footprint
    • 12.5.5.2 Region footprint
    • 12.5.5.3 Product footprint
    • 12.5.5.4 Application footprint
    • 12.5.5.5 End-user footprint
• 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 12.6.1 PROGRESSIVE COMPANIES
  • 12.6.2 RESPONSIVE COMPANIES
  • 12.6.3 DYNAMIC COMPANIES
  • 12.6.4 STARTING BLOCKS
  • 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 12.6.5.1 Detailed list of key startups/SMEs
    • 12.6.5.2 Competitive benchmarking of startups/SMEs
• 12.7 COMPANY VALUATION & FINANCIAL METRICS
  • 12.7.1 FINANCIAL METRICS
  • 12.7.2 COMPANY VALUATION
• 12.8 BRAND/PRODUCT COMPARISON
• 12.9 COMPETITIVE SCENARIO
  • 12.9.1 PRODUCT LAUNCHES & APPROVALS
  • 12.9.2 DEALS
  • 12.9.3 EXPANSIONS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 GETINGE
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Product launches
      • 13.1.1.3.2 Expansions
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Right to win
      • 13.1.1.4.2 Strategic choices
      • 13.1.1.4.3 Weaknesses & competitive threats
  • 13.1.2 MEDTRONIC
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products offered
    • 13.1.2.3 MnM view
      • 13.1.2.3.1 Right to win
      • 13.1.2.3.2 Strategic choices
      • 13.1.2.3.3 Weaknesses & competitive threats
  • 13.1.3 TERUMO CORPORATION
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Deals
      • 13.1.3.3.2 Expansions
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Right to win
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses & competitive threats
  • 13.1.4 FRESENIUS MEDICAL CARE AG
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products offered
    • 13.1.4.3 Recent developments
      • 13.1.4.3.1 Deals
    • 13.1.4.4 MnM view
      • 13.1.4.4.1 Right to win
      • 13.1.4.4.2 Strategic choices
      • 13.1.4.4.3 Weaknesses & competitive threats
  • 13.1.5 LIVANOVA PLC
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products offered
    • 13.1.5.3 MnM view
      • 13.1.5.3.1 Right to win
      • 13.1.5.3.2 Strategic choices
      • 13.1.5.3.3 Weaknesses & competitive threats
  • 13.1.6 NIPRO
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products offered
  • 13.1.7 WEIGAO GROUP CO., LTD.
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products offered
  • 13.1.8 ABBOTT
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products offered
    • 13.1.8.3 Recent developments
      • 13.1.8.3.1 Product approvals
  • 13.1.9 MICROPORT SCIENTIFIC CORPORATION
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products offered
  • 13.1.10 EUROSETS
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products offered
• 13.2 OTHER PLAYERS
  • 13.2.1 SPECTRUM MEDICAL
  • 13.2.2 SENKO MEDICAL INSTRUMENT MFG. CO., LTD.
  • 13.2.3 CHALICE MEDICAL LTD.
  • 13.2.4 MAGASSIST CO., LTD.
  • 13.2.5 BRAILE BIOMEDICA
  • 13.2.6 GIZMOMED PRIVATE LIMITED
  • 13.2.7 ORIGEN BIOMEDICAL, INC.
  • 13.2.8 ABIOMED
  • 13.2.9 ANDOCOR
  • 13.2.10 JIANGSU STMED TECHNOLOGY CO., LTD.
  • 13.2.11 CARDIOQUIP
  • 13.2.12 CBM LIFEMOTION
  • 13.2.13 CHANGZHOU KANGXIN MEDICAL INSTRUMENTS
  • 13.2.14 GENTHERM

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS